Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib Value in Health Oct 11 Written by Matthijs Versteegh Oncologypersonalized medicine Matthijs Versteegh Previous Previous The economics of patents and innovation in pharma Next Next Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib Value in Health Oct 11 Written by Matthijs Versteegh Oncologypersonalized medicine Matthijs Versteegh
